NCT00806208 - Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

January 31, 2000

Study Completion Date

March 31, 2000

Conditions

Graft-Versus-Host Disease

Interventions

DRUG

MEDI-507

0.012 mg/kg MEDI 507 and Methylprednisolone

DRUG

MEDI-507

0.04 mg/kg MEDI 507 and Methylprednisolone

DRUG

MEDI-507

0.12 mg/kg MEDI 507 and Methylprednisolone

DRUG

MEDI-507

0.4 mg/kg MEDI 507 and Methylprednisolone

OTHER

Placebo

Placebo IV (alternative) study days 0, 3,6, and 9

Trial Locations (3)

Washington University Medical Center, St Louis

Baylor Institute of Transplant Sciences, Dallas

University of Nebraska Medical Center, Omaha